PATENT CLAIM ANALYSIS

Application Number: 15986332
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "046000"]

Abstract:
Provided is an A 3 AR ligand for reducing ectopic fat accumulation, particularly in fatty liver. Further provided is the use of A 3 AR ligand for the preparation of a pharmaceutical composition for reducing such fat accumulation, method of treating a condition associates with fat accumulation making use of the ligand and kits including pharmaceutical compositions including the ligand, and instructions for use of same, for treating a condition associated with ectopic fat accumulation. Further provided is the use of an A 3 AR agonist, such as 2-Chloro-N 6 -(3-iodobenzyl)-adenosine-5′-N-methyluronamide (Cl-IB-MECA, CF102) for treating fatty liver, specifically, non-alcoholic fatty liver disease (NAFLD).

Claim (Index 51):
The method of  claim 47 , comprising chronic administration of said A 3 AR ligand.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 93.0
- Lexical Diversity: 2.17857
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14420439', '13320715', '15160462', '11604905', '13386339']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7350633929097407
- 35 USC 102 Novelty (BERT): 0.4970915292894465
- Combined Prediction Score: 0.7112662065477112
- Mean Citation Score: 190.585484
- Max Citation Score: 222.2446
- Similarity Product: 152.1661379748106

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test